According to Esperion Therapeutics's latest financial reports the company's current revenue (TTM) is $0.11 B. In 2022 the company made a revenue of $75.47 M a decrease over the years 2021 revenue that were of $78.44 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.11 B | 54.14% |
2022 | $75.47 M | -3.79% |
2021 | $78.44 M | -65.52% |
2020 | $0.22 B | 53.37% |
2019 | $0.14 B | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A | |
2012 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Pfizer PFE | $58.49 B | 50,183.67% | ๐บ๐ธ USA |
Regeneron Pharmaceuticals REGN | $13.11 B | 11,175.47% | ๐บ๐ธ USA |
Ultragenyx RARE | $0.43 B | 273.28% | ๐บ๐ธ USA |
Lexicon Pharmaceuticals
LXRX | $1.2 M | -98.96% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | $0.39 B | 243.28% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $2.41 B | 1,979.55% | ๐บ๐ธ USA |